CDK4 and prostate carcinoma: It has been previously shown through in vitro studies that cyclin D1 can influence androgen-dependent prostate cancer cell proliferation through its dual ability to modulate both CDK4 and AR activity (Petre-Draviam et al, 2005; Burd et al, 2006a).